



Nonsense-Mediated mRNA Decay: From Molecular Mechanism to Therapeutic Perspectives

Guest Editor:

Dr. Fabrice Lejeune

CANTHER—Cancer
Heterogeneity, Plasticity and
Resistance to Therapies, CHU
Lille, Institut Pasteur de Lille,
INSERM, UMR9020-U1277,
Université de Lille, 59000 Lille,
France

Deadline for manuscript
submissions:

closed (31 January 2022)

Message from the Guest Editor

The most-studied quality-control mechanism is certainly that responsible for eliminating mRNAs carrying a premature stop codon, called nonsense-mediated mRNA decay (NMD). The interest in NMD also comes from the fact that its role as a cell cleaner of mRNAs carrying premature stop codons links it to the origin of approximately 10% of cases of genetic diseases. Some groups therefore seek to inhibit it, while others rather try to activate it, by means of various molecules, in order to propose new therapeutic approaches for the treatment of genetic diseases but also to study the mechanism of NMD in a particular configuration. Much remains to be learned about this mechanism for understanding the chains of reactions and interactions that lead to letting an mRNA continue its translation or, on the contrary, very quickly degrading an mRNA carrying a premature stop codon. This Special Issue aims to provide up-to-date molecular insight into the nonsense-mediated mRNA decay mechanism, its regulation and its involvement in various pathologies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)